Clinical trial
A Phase III Trial to Evaluate the Efficacy and Safety of JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan
NCT07384377 is registered in ClinicalTrials.gov with Shanghai JMT-Bio Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III Trial to Evaluate the Efficacy and Safety of JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan
- Lead sponsor
- Shanghai JMT-Bio Inc.
- Phase
- Phase 3
- Overall status
- Not yet recruiting
- Start date
- February 6, 2026
- Completion date
- June 15, 2028
- Enrollment
- 123 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
her2-positive colorectal cancer